CJC-1295/Ipamorelin Blend

CJC-1295/Ipamorelin Blend combines two complementary growth hormone-releasing peptides into a single preparation for synergistic stimulation of natural growth hormone (GH) secretion. CJC-1295 (without DAC), also known as Modified GRF 1-29 or Mod GRF, is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to produce GH. Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R) agonist that mimics ghrelin to trigger GH release. When combined, these two peptides amplify GH output beyond what either achieves alone by activating both the GHRH and ghrelin receptor pathways simultaneously.

Mechanism of Action

CJC-1295 (no DAC) binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating cyclic AMP signaling and subsequent growth hormone synthesis and release. It is a truncated and modified analog of endogenous GHRH (amino acids 1-29) with amino acid substitutions at positions 2, 8, 15, and 27 that confer resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), extending its active half-life compared to native GHRH.

Ipamorelin acts on the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by endogenous ghrelin. Unlike other GHS-R agonists such as GHRP-6, Ipamorelin is highly selective for GH release and does not significantly elevate cortisol, prolactin, or aldosterone at standard doses. This selectivity is attributed to its pentapeptide structure (Aib-His-D-2-Nal-D-Phe-Lys-NH2) which provides a clean GH pulse without the broader hormonal perturbations seen with less selective secretagogues.

The synergy between these two peptides arises because GHRH receptor activation primes the pituitary for GH release while GHS-R activation triggers the release itself. Together they produce a larger, more physiologic GH pulse that mimics the body’s natural pulsatile secretion pattern. This combination also preserves the negative feedback loop, meaning GH release is still modulated by somatostatin, reducing the risk of supraphysiologic GH levels.

Research Evidence

Teichman et al. (2006, Journal of Clinical Endocrinology & Metabolism): demonstrated that CJC-1295 increases mean GH concentrations 2- to 10-fold and IGF-1 levels 1.5- to 3-fold in healthy subjects over 6-14 days with dose-dependent responses. Raun et al. (1998, European Journal of Endocrinology): the original characterization of Ipamorelin showing potent, selective GH release in swine models without significant effects on ACTH or cortisol.

Anderson et al. (2001): showed Ipamorelin produced consistent GH release over repeated dosing without desensitization in human subjects. Veldhuis et al. (2005): demonstrated that combining GHRH analogs with ghrelin-mimetics produces synergistic GH release exceeding the sum of individual effects, supporting the pharmacologic rationale for the CJC-1295/Ipamorelin combination.

Clinical Applications

The CJC-1295/Ipamorelin combination is primarily used in clinical and wellness settings for age-related growth hormone decline, body composition optimization, improved recovery from exercise or injury, and enhanced sleep quality. Practitioners report improvements in lean body mass, reduction in visceral adiposity, improved skin elasticity, and better sleep architecture with consistent use. The combination is favored over exogenous GH administration because it stimulates natural, pulsatile GH release rather than providing a flat, supraphysiologic dose, theoretically preserving the hypothalamic-pituitary axis feedback mechanisms.